Please login to the form below

Not currently logged in
Email:
Password:

Abbott and Zydus emerging markets deal

Abbott has entered into an agreement with India's Zydus Cadila relating to a portfolio of products that it will commercialise in 15 emerging markets

Abbott has entered into a licensing and supply agreement with India-based Zydus Cadila. The deal relates to a portfolio containing at least 24 Zydus products, which Abbott will commercialise in 15 key emerging markets where Abbott already has a strong and growing presence.

As part of the agreement, more than 40 additional Zydus products could be added to the collaboration deal. The partnership covers medicines for pain, cancer and cardiovascular, neurological and respiratory diseases. Product launches are expected to commence in early 2012.

Abbott has also created a stand-alone Established Products Division (EPD) that will concentrate on expanding access to non-US markets, particularly emerging markets, for Abbott's established pharmaceutical products.

"Our new Established Products Division, with $5bn in sales, wll focus on expanding our presence and product offerings in the world's fastest-growing emerging markets," said Olivier Bohuon, executive vice president, Pharmaceutical Products Group, Abbott.

Abbott has a large portfolio of branded generics, which the company has built up over the past 10 years, Abbott's acquisition of Solvay earlier this year helped the company to gain significant critical mass in key emerging markets.

12th May 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Grace Communications

Grace Communications is an award winning, independent, full service, creative communications agency specialising in solving problems for healthcare brands....

Latest intelligence

Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...
Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...

Infographics